S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models
Lauren R. Begg(Northwestern University), Dai Horiuchi(Northwestern University)
Cited by 7
Related Papers
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
|The Journal of Experimental Medicine|2012|395
S100A8/A9 predicts triple-negative breast cancer response to PIM kinase and PD-1/PD-L1 inhibition
|bioRxiv (Cold Spring Harbor Laboratory)|2023|1